Personalis Inc. (PSNL)
5.43
-0.40 (-6.78%)
At close: Feb 20, 2025, 3:59 PM
5.35
-1.47%
After-hours: Feb 20, 2025, 06:32 PM EST
undefined% (undefined)
| Bid | 5.12 |
| Market Cap | 385.64M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.73 |
| PE Ratio (ttm) | -3.14 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.7 |
| Volume | 954,140 |
| Avg. Volume (20D) | 1,138,491 |
| Open | 5.74 |
| Previous Close | 5.83 |
| Day's Range | 5.15 - 5.71 |
| 52-Week Range | 1.14 - 7.20 |
| Beta | undefined |
About PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from ...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Jun 20, 2019
Employees 223
Stock Exchange NASDAQ
Ticker Symbol PSNL
Website https://www.personalis.com
Analyst Forecast
According to 4 analyst ratings, the average rating for PSNL stock is "Buy." The 12-month stock price forecast is $7.62, which is an increase of 40.33% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Personalis Inc. is scheduled to release its earnings on Feb 27, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+9.32%
Personalis shares are trading higher after the com...
Unlock content with
Pro Subscription
2 months ago
+47.75%
Moderna and Personalis shares are trading higher after signing a multi-year extension to continue utilizing the Personalis ImmunoID NeXT platform and technology for V940/mRNA-4157.
